Skip to Content

Generic Acuvail Availability

Acuvail is a brand name of ketorolac ophthalmic, approved by the FDA in the following formulation(s):

ACUVAIL (ketorolac tromethamine - solution/drops;ophthalmic)

  • Manufacturer: ALLERGAN
    Approval date: July 22, 2009
    Strength(s): 0.45% [RLD] [AT]

Has a generic version of Acuvail been approved?

No. There is currently no therapeutically equivalent version of Acuvail available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Acuvail. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Ketorolac tromethamine compositions for treating ocular pain
    Patent 7,842,714
    Issued: November 30, 2010
    Inventor(s): Farnes; Eldon Q. & Attar; Mayssa & Schiffman; Rhett M. & Chang; Chin-Ming & Graham; Richard S. & Welty; Devin F.
    Assignee(s): Allergan, Inc.
    The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
    Patent expiration dates:
    • August 15, 2029
      Drug substance
      Drug product
  • Compositions for delivery of therapeutics into the eyes and methods for making and using same
    Patent 8,512,717
    Issued: August 20, 2013
    Assignee(s): Allergan, Inc.
    The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.
    Patent expiration dates:
    • March 7, 2028
      Drug product
  • Patent 8,992,952
    Patent expiration dates:
    • August 5, 2024
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ATTopical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data.